ClinicalTrials.gg
CompletedNCT00050011Updated Mar 21, 2014Results posted

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

A Phase 3 interventional study of Zoledronic Acid and Letrozole in Breast Neoplasms and Osteoporosis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 2 countries. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-03-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.

Enrollment
9th of 56
602 · median 98
Started
2002
with 4 others
Phase 3
24 of 59
none open now
Registered
4th of 59
by date
Lead sponsor
11 of 59
Novartis Pharmaceuticals

Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 9th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2002, is one of 24 in phase 3, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing Zoledronic Acid in Breast Neoplasms as a file.
02

Study summary

This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip, or any clinical fracture unrelated to trauma, or an asymptomatic fracture discovered at the month 36 scheduled visit) in stage I-IIIb postmenopausal women with hormone receptor positive breast cancer who will receive Letrozole 2.5 mg daily as an adjuvant therapy.

03

Conditions studied

  • Breast Neoplasms
  • Osteoporosis

Keywords

  • cancer-treatment related bone loss
  • postmenopausal women
  • breast cancer
  • hormone receptor positive breast cancer
  • adjuvant therapy
  • hormonal therapy
  • bone loss
  • bisphosphonates
  • ZFAST
  • Letrozole
  • Zoledronic Acid
  • US32
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. status defined by one of the following :

    • women equal to or greater than 55 years with cessation of menses
    • spontaneous cessation of menses within the past 1 year, but amenorrheic in women less than or equal to 55 years (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (follicle stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (\< 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved
    • bilateral oophorectomy (prior to the diagnosis of breast cancer).
  3. Adequately diagnosed and treated breast cancer defined as:

    • Patients with breast cancer whose tumor can be removed by an appropriate surgical procedure such as mastectomy or breast conserving surgery and who receive appropriate additional local treatments such as radiotherapy according to best practice.
    • Patients must be at the end of their local treatment without evidence of local residual disease.
    • Patients must have no clinical or radiological evidence of distant .
  4. Hormone receptor positive defined as:

    • ER and/or PR greater than or equal to1 0 fmol/mg cytosol protein; or greater than or equal to 10% of the tumor cells positive by
    • immunohistochemical evaluation.
  5. Patients with a baseline lumbar spine and total hip BMD T-score at or above -2.0 SD are eligible.
  6. Patients who will receive chemotherapy are eligible for participation. Adjuvant chemotherapy must be completed prior to randomization.
  7. The date of randomization must not be more than the following:

    • 12 weeks from completion of surgery;
    • 12 weeks after completion of adjuvant chemotherapy;
    • 12 weeks after completion of surgery and radiation therapy; however the patient may be randomized while receiving radiation therapy - this decision is at the Investigator's discretion.
    • 12 weeks after completion of chemotherapy and radiation therapy; however, the patient may be randomized while receiving radiation therapy - this decision is at the Investigator's discretion.
  8. Patients who have undergone neoadjuvant chemotherapy are eligible.
  9. No prior treatment with Femara.

Exclusion criteria

Exclusion criteria:

  1. Patients with any clinical or radiological evidence of distant spread of their disease at any point before randomization.
  2. Patients with clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip.
  3. Patients with a history of fracture with low-intensity or no associated trauma.
  4. Patients who have started hormonal therapy or who have completed adjuvant hormonal therapy prior to randomization.
  5. Patients who have received any endocrine therapy within the past 12 months (other than neoadjuvant tamoxifen or toremifene, insulin and/or oral anti-diabetic medications, and thyroid hormone replacement). Hormone replacement therapy must be discontinued prior to randomization.
  6. Patients who have received prior treatment with intravenous bisphosphonates within the past 12 months.
  7. Patients currently receiving oral bisphosphonates. Oral bisphosphonates must be discontinued within 3 weeks of baseline evaluations.
  8. Patients who have received prior treatment with systemic within the past 12 months (short term corticosteroid therapy, e.g. to prevent/treat chemotherapy-induced nausea/vomiting, is acceptable).
  9. Patients with prior exposure to anabolic steroids or growth hormone within the past 6 months.
  10. Patients with prior use of Tibolone within the last 6 months.
  11. Any prior use of PTH for more than 1 week.
  12. Prior use of systemic sodium fluoride for > 3 months during the past 2 years.
  13. Patients currently treated with any drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate) within 2 weeks prior to randomization.
  14. Patients with previous or concomitant (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for five years.
  15. Patients with other non-malignant systemic diseases including uncontrolled infections, uncontrolled type 2 diabetes mellitus, uncontrolled thyroid dysfunction, cardiovascular, renal, hepatic, and lung diseases which would prevent prolonged follow-up. Patients with previous history of thrombosis or thromboembolism can be included only if medically suitable. Patients with a known history of are excluded.
  16. Uncontrolled seizure disorders associated with falls.
  17. Patients with abnormal renal function as evidenced by a serum creatinine equal to or greater than 3 mg/dL (265.2 mmol/L).
  18. History of diseases with influence on bone metabolism, such as Paget's disease, Osteogenesis Imperfecta, and primary or secondary hyperthyroidism within 12 months prior to study entry.
  19. Patients with baseline lumber spine or total hip BMD T-score below -2.0 SD.
  20. Patients treated with systemic drug(s) and/or device(s) within the past 30 days or topical investigational drugs within the past 7 days.

Additional Exclusion Criteria: (for Spine DXA)

  • History of surgery at the lumbosacral spine, with or without implantable devices.
  • Scoliosis with a Cobb angle >15 degree at the lumbar spine.
  • Immobility, hyperostosis or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan.
  • Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA.

Additional protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
602 participants (actual)

Study arms

  • Experimental
    Zoledronic Acid upfront

    Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.

    Drug: Zoledronic Acid · Drug: Letrozole

  • Experimental
    Zoledronate delayed-start

    In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.

    Drug: Zoledronic Acid · Drug: Letrozole

Interventions

  • Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.

    Also known as: ZOL446, Zoledronate

  • Participants received Letrozole 2.5 mg daily.

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)

    Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Month 12 - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Percent Change From Baseline in Lumbar Spine (L1-L4) BMD

    Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data beyond month 12 were not imputed by LOCF.

    Time frame: Baseline, 2 years, 3 years, 5 years

  2. Percent Change From Baseline in Total Hip BMD

    Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.

    Time frame: Baseline, 12 months, 2 years, 3 years, 5 years

  3. Percent Change From Baseline in Biochemical Markers of Bone Turnover, Serum N-Telopeptide (sNTX) and Bone-specific Alkaline Phosphatase (BSAP)

    Blood samples from a subset of participants (231 participants in total) were collected to measure the sNTX and BSAP. Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from months 6 and 9 were carried forward to month 12. Data prior to month 6 were not carried forward. Missing data beyond month 12 were not imputed by LOCF.

    Time frame: Baseline, 12 months, 2 years, 3 years, 5 years

  4. Incidence Rate of All Clinical Fractures

    The number of participants who experienced a clinical fracture at month 36 was assessed. Initial x-ray (both AP and lateral views) of the lumbar and thoracic spine were performed at baseline to exclude participants with evidence of fracture. In addition, repeated bone scan and/or x-ray were performed at the Principal Investigator's discretion during the course of the study to confirm evidence of clinical fracture, or at month 36 if there was no evidence of clinical fracture (lumbar and thoracic spine - lateral view). X-ray films were sent to a central reader.

    Time frame: 3 years

  5. Time to Disease Recurrence/Relapse

    The median time to disease progression was assessed by Kaplan-Meier analysis. The Principal Investigator assessed each participant for disease recurrence at each visit. Further testing was performed at the discretion of the Principal Investigator and as clinically indicated. Disease progression was defined as chest wall and/or regional recurrence confirmed by positive cytology or biopsy, and/or distance recurrence of the 1) skin, subcutaneous tissue, and lymph nodes (other than local or regional), 2) bone marrow, 3) lung, 4) skeleton 5) liver and 6) central nervous system confirmed by positive cytology, biopsy, aspirate or radiology as appropriate.

    Time frame: over 5 years

  6. Rate of Change From Baseline in Lumbar Spine (L1-L4) BMD

    The rate of change from baseline in BMD was assessed.

    Time frame: Baseline, 5 years

  7. Rate of Change From Baseline in Total Hip BMD

    The rate of change from baseline in BMD was assessed.

    Time frame: Baseline, 5 years

07

Results

Posted Jan 28, 2014

Participant flow

Participant flow — Overall Study
MilestoneZoledronic Acid UpfrontZoledronic Acid Delayed-start
Started301301
Intent-to-treat population300300
Completed180175
Not completed121126
Withdrew: Adverse event4146
Withdrew: Abnormal laboratory value(s)11
Withdrew: Abnormal test procedure results01
Withdrew: Lack of efficacy1621
Withdrew: Participant condition no longer required10
Withdrew: Protocol violation410
Withdrew: Withdrawal by subject3426
Withdrew: Lost to follow-up79
Withdrew: Administrative problems106
Withdrew: Death74
Withdrew: Unknown - reason is missing02

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)

Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Month 12 - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the last observation carried forward (LOCF) method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.

Time frame:
Baseline, 12 months
Reported as:
Mean · Percentage of BMD
Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)
Percentage of BMDZoledronic Acid UpfrontZoledronic Acid Delayed-start
Percent Change From Baseline in Lumbar Spine (L1-L4) Bone Mineral Density (BMD)1.955 ± 3.3658-2.325 ± 3.9542
SecondaryPercent Change From Baseline in Lumbar Spine (L1-L4) BMD

Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data beyond month 12 were not imputed by LOCF.

Time frame:
Baseline, 2 years, 3 years, 5 years
Reported as:
Mean · Percentage of BMD
Percent Change From Baseline in Lumbar Spine (L1-L4) BMD
Percentage of BMDZoledronic Acid UpfrontZoledronic Acid Delayed Start
2 years (n=206,202)3.137 ± 4.1599-2.889 ± 5.0783
3 years (n=189,190)3.853 ± 4.5414-2.990 ± 5.7925
5 years (n=140,132)6.192 ± 5.9723-2.418 ± 7.4545
SecondaryPercent Change From Baseline in Total Hip BMD

Bone mineral density (BMD) measurements were assessed by dual energy x-ray absorptiometry (DXA). The DXA devices of participating sites were cross-calibrated and the DXA results were compiled and analyzed by a central reader. Percent change = 100\*((BMD at Time Frame - Baseline BMD)/Baseline BMD)). Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from month 6 were carried forward to month 12. Data prior to month 6 were not carried forward.

Time frame:
Baseline, 12 months, 2 years, 3 years, 5 years
Reported as:
Mean · Percentage of BMD
Percent Change From Baseline in Total Hip BMD
Percentage of BMDZoledronic Acid UpfrontZoledronic Acid Delayed Start
12 months (n=253,256)1.256 ± 2.5878-1.883 ± 3.3007
2 years (n=208,200)1.413 ± 2.9178-3.150 ± 4.0450
3 years (n=187,189)1.676 ± 3.6979-3.463 ± 5.2585
5 years (n=141,132)2.571 ± 4.8794-4.115 ± 6.1071
SecondaryPercent Change From Baseline in Biochemical Markers of Bone Turnover, Serum N-Telopeptide (sNTX) and Bone-specific Alkaline Phosphatase (BSAP)

Blood samples from a subset of participants (231 participants in total) were collected to measure the sNTX and BSAP. Missing data at month 12 were imputed by using the LOCF method. Post-baseline non-missing data from months 6 and 9 were carried forward to month 12. Data prior to month 6 were not carried forward. Missing data beyond month 12 were not imputed by LOCF.

Time frame:
Baseline, 12 months, 2 years, 3 years, 5 years
Reported as:
Mean · Percentage of biochemical markers
Percent Change From Baseline in Biochemical Markers of Bone Turnover, Serum N-Telopeptide (sNTX) and Bone-specific Alkaline Phosphatase (BSAP)
Percentage of biochemical markersZoledronic Acid UpfrontZoledronic Acid Delayed Start
sNTX, 12 months (n=87,85)-20.1 ± 42.121.7 ± 55.2
sNTX, 2 yearsNA ± NANA ± NA
sNTX, 3 yearsNA ± NANA ± NA
sNTX, 5 yearsNA ± NANA ± NA
BSAP, 12 months (n=88,90)-7.8 ± 28.219.0 ± 39.2
BSAP, 2 years (n=63,60)-12.0 ± 26.319.9 ± 48.1
BSAP, 3 years (n=59,52)-12.4 ± 23.210.6 ± 42.2
BSAP, 5 years (n=95,102)-6.4 ± 35.411.9 ± 41.0
SecondaryIncidence Rate of All Clinical Fractures

The number of participants who experienced a clinical fracture at month 36 was assessed. Initial x-ray (both AP and lateral views) of the lumbar and thoracic spine were performed at baseline to exclude participants with evidence of fracture. In addition, repeated bone scan and/or x-ray were performed at the Principal Investigator's discretion during the course of the study to confirm evidence of clinical fracture, or at month 36 if there was no evidence of clinical fracture (lumbar and thoracic spine - lateral view). X-ray films were sent to a central reader.

Time frame:
3 years
Reported as:
Number · Participants
Incidence Rate of All Clinical Fractures
ParticipantsZoledronic Acid UpfrontZoledronic Acid Delayed Start
Incidence Rate of All Clinical Fractures1821
SecondaryTime to Disease Recurrence/Relapse

The median time to disease progression was assessed by Kaplan-Meier analysis. The Principal Investigator assessed each participant for disease recurrence at each visit. Further testing was performed at the discretion of the Principal Investigator and as clinically indicated. Disease progression was defined as chest wall and/or regional recurrence confirmed by positive cytology or biopsy, and/or distance recurrence of the 1) skin, subcutaneous tissue, and lymph nodes (other than local or regional), 2) bone marrow, 3) lung, 4) skeleton 5) liver and 6) central nervous system confirmed by positive cytology, biopsy, aspirate or radiology as appropriate.

Time frame:
over 5 years
Reported as:
Median · months
Time to Disease Recurrence/Relapse
monthsZoledronic Acid UpfrontZoledronic Acid Delayed Start
Time to Disease Recurrence/RelapseNA (NA to NA)NA (NA to NA)
SecondaryRate of Change From Baseline in Lumbar Spine (L1-L4) BMD

The rate of change from baseline in BMD was assessed.

Time frame:
Baseline, 5 years
Reported as:
Mean · g/sq cm/month
Rate of Change From Baseline in Lumbar Spine (L1-L4) BMD
g/sq cm/monthZoledronic Acid UpfrontZoledronic Acid Delayed Start
Rate of Change From Baseline in Lumbar Spine (L1-L4) BMD0.01043 (0.00810 to 0.01277)-0.00157 (-0.00396 to 0.00081)
SecondaryRate of Change From Baseline in Total Hip BMD

The rate of change from baseline in BMD was assessed.

Time frame:
Baseline, 5 years
Reported as:
Mean · g/sq. cm/month
Rate of Change From Baseline in Total Hip BMD
g/sq. cm/monthZoledronic Acid UpfrontZoledronic Acid Delayed Start
Rate of Change From Baseline in Total Hip BMD0.00226 (0.00071 to 0.00382)-0.00625 (-0.00784 to -0.00466)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid Upfront—83/300 (27.7%)283/300 (94.3%)
Zoledronic Acid Delayed-start—71/300 (23.7%)275/300 (91.7%)
Most frequent serious events
Showing 10 of 197
Most frequent serious events
EventZoledronic Acid UpfrontZoledronic Acid Delayed-start
FallInjury, poisoning and procedural complications10/3007/300
OsteoarthritisMusculoskeletal and connective tissue disorders9/3009/300
Atrial fibrillationCardiac disorders4/3004/300
Coronary artery diseaseCardiac disorders1/3004/300
Coronary artery occlusionCardiac disorders0/3004/300
CholecystitisHepatobiliary disorders4/3002/300
PneumoniaInfections and infestations4/3003/300
Deep vein thrombosisVascular disorders3/3004/300
Chest painGeneral disorders3/3001/300
AppendicitisInfections and infestations1/3003/300
Most frequent other events
Showing 10 of 41
Most frequent other events
EventZoledronic Acid UpfrontZoledronic Acid Delayed-start
ArthralgiaMusculoskeletal and connective tissue disorders141/300136/300
Hot flushVascular disorders122/300118/300
FatigueGeneral disorders101/30088/300
MyalgiaMusculoskeletal and connective tissue disorders61/30047/300
Back painMusculoskeletal and connective tissue disorders44/30052/300
Bone painMusculoskeletal and connective tissue disorders48/30024/300
Pain in extremityMusculoskeletal and connective tissue disorders45/30040/300
DepressionPsychiatric disorders35/30042/300
InsomniaPsychiatric disorders41/30029/300
NauseaGastrointestinal disorders39/30040/300

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zoledronic Acid UpfrontZoledronic Acid Delayed-startTotal
Mean61.4 ± 9.2861.0 ± 8.9261.2 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic Acid UpfrontZoledronic Acid Delayed-startTotal
Female301301602
Male000
08

Study locations

44 sites
  • Highlands Oncology Group
    Springdale, Arkansas 72764, United States
  • East Valley Hematology & Oncology
    Burbank, California 91505, United States
  • Louisiana Oncology Associates
    Lafayette, California 70506, United States
  • Wilshire Oncology Medical Group
    LaVerne, California 91750, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Clinical Trials & Research Associates, Inc.
    Montebello, California 90640, United States
  • Redwood Regional Medical Group
    Santa Rosa, California 95403, United States
  • Cancer and Blood Institute of the Desert
    Rancho Mirage, Colorado 92270, United States
  • Eastern Connecticut Hematology/Oncology Associates
    Norwich, Connecticut 06360, United States
  • FL Community Cancer Center
    Brooksville, Florida 34613, United States
  • Robert R. Carroll, MD, PA
    Gainesville, Florida 32605, United States
  • Oncology Hematology Group of South Florida
    Miami, Florida 33176, United States
  • Pasco Pinellas Cancer Center
    New Port Richey, Florida 34652, United States
  • Ocala Oncology Center
    Ocala, Florida 33479, United States
  • Cancer Research Network, Inc.
    Plantation, Florida 33324, United States
  • Bay Area Oncology
    Tampa, Florida 33607, United States
  • Space Coast Medical
    Titusville, Florida 32796, United States
  • Elmhurst Memorial Hospital
    Elhurst, Illinois 60126, United States
  • Kentuckiana Cancer Institute
    Louisville, Kentucky 40202, United States
  • Frederick Memorial Hospital Regional Cancer Therapy Center
    Frederick, Maryland 21701, United States
  • New England Hematology/Oncology Associates
    Wellesley, Massachusetts 02481, United States
  • Cook Research Department at Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • Metro Minnesota CCOP
    St. Louis Park, Minnesota 55416, United States
  • Hematology-Oncology Centers of the Northern Rockies, PC
    Billings, Montana 59101, United States
  • Methodist Cancer Center
    Omaha, Nebraska 68114, United States
  • Hematology-Oncology Associates of Northern NJ
    Morristown, New Jersey 07962, United States
  • New Mexico Oncology Hematology, Ltd.
    Albuquerque, New Mexico 87109, United States
  • Hemoncare PC
    Brooklyn, New York 11235, United States
  • Odyssey Research Services
    Bismarck, North Dakota 58501, United States
  • Nashat Y. Gabrail MD Inc.
    Canton, Ohio 44718, United States
  • Oncology Partners Network
    Cincinnati, Ohio 45238, United States
  • Physician Associates, Inc.
    Cincinnati, Ohio 45238, United States
  • Dayton Clinical Oncology Program
    Dayton, Ohio 45420, United States
  • University of Pittsburgh Cancer Institute/Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Charleston Hematology Oncology
    Charleston, South Carolina 29403, United States
  • The Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • St. Joseph Regional Cancer Center
    Bryan, Texas 77802, United States
  • Cancer Specialists of South Texas
    Corpus Christi, Texas 78412, United States
  • Center for Oncology Research & Tx. PA
    Dallas, Texas 75230, United States
  • Northern Virginia Oncology Group
    Fairfax, Virginia 22031, United States
  • Virginia Physicians, Inc.- Oncology
    Richmond, Virginia 23294, United States
  • Swedish Cancer Institute
    Seattle, Washington 98122, United States
  • Rockwood Clinic, PS
    Spokane, Washington 99220, United States
  • VA Medical Center
    San Juan, 00927, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2002
First posted
Nov 20, 2002
Start
Sep 2002
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Jan 28, 2014
Last update
Mar 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00050011
Responsible party
Sponsor
First posted
Nov 20, 2002
Start date
Sep 2002
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Jan 28, 2014
Last update
Mar 21, 2014

Study contacts

Novartis Pharmaceuticals, MD
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zoledronic Acid · Letrozole

Start the discussion